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Mini Abstract 
This study investigates the immunological role of elevated IL-6 post-operatively. Although increased IL-6 
is associated with post-operative infections, the immunosuppressive properties of post-operative serum 
are not reversed with IL-6 neutralisation but are with IFN-γ administration. Elevated post-operative IL-6 
may represent an epiphenomenon in the context of post-operative immunosuppression. 
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Abstract 
Objective 
To evaluate the role of IL-6 pathways in post-operative immune-suppression and to assess the 
reversibility of this phenomenon. 
Background 
The post-operative period is characterised by increased IL-6 production and features of immune-
suppression. In vitro, IL-6 mediates anti-inflammatory effects through inhibition of interferon-gamma 
(IFN-γ) pathways. The significance of the immunomodulatory effects of IL-6 in the clinical setting of 
post-operative immune-suppression remains unclear. 
Methods 
Patients over 45 years old undergoing elective surgery involving the gastrointestinal tract were 
recruited. IL-6 levels were assayed using ELISA pre-operatively, at 24 and 48hrs. Peripheral blood 
mononuclear cells (PBMCs) from healthy volunteers were cultured in perioperative serum and 
CD14
+
HLA-DR (mHLA-DR) geometric-mean florescent intensity (MFI) was measured in the presence 
and absence of IL-6 neutralising antibody and recombinant IFN-γ. 
Results 
Of 108 patients, 41 developed a post-operative infection. IL-6 levels increased 19-fold from the 
pre-operative sample to 24hrs post-operatively (P<0.0001). Higher IL-6 levels at 24 (P=0.0002) and 
48hrs (P=0.003) were associated with subsequent post-operative infectious complications. mHLA-DR 
MFI fell when healthy PBMCs were cultured with post-operative serum compared to pre-operative serum 
(P=0.008). This decrease was prevented by the presence of IFN-γ in the culture media but not by the 
presence of IL-6 neutralising antibody.    
 4 
Conclusions 
IL-6 levels increase following major surgery and are associated with an increased susceptibility to 
post-operative infections. Serum obtained from post-operative patients induces an immunosuppressive 
response, reflected in reduced mHLA-DR levels, mediated through IL-6 independent pathways but 
reversible with IFN-γ. These data may have therapeutic implications for the prevention of infection in 
patients undergoing major surgery.  
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Introduction 
 
Following major surgery patients experience a period of immune suppression, which can 
predispose to the development of post-operative infections.
1
 Infectious complications result in 
considerable morbidity and are observed in over 30% of older patients undergoing major surgery.
2
 Post-
operative immune dysfunction is mediated partly by tissue injury and the consequent release of 
intracellular alarmins such as mitochondrial DNA fragments.
3
 The cellular and transcriptomic features of 
tissue damage induced immune modulation are now well characterised.
4-6
 Key reproducible cellular 
features of this response include a consistent fall in monocyte HLA-DR (mHLA-DR) expression
1, 7, 8
 and 
an expansion of cells with phenotypic similarities to myeloid derived suppressor cells.
4, 5, 9
 These 
alterations are quantitatively associated with infectious complications and poor functional recovery.
1, 4, 8
 
Although the immune suppressive effect of major tissue damage has been shown to be reversible with 
interferon gamma (IFN-γ) treatment in the context of traumatic injuries,10-12 in the perioperative period 
the specific additional immunomodulating effects attributable to such factors as prolonged anaesthetic 
administration, opioid analgesics, premorbid conditions and blood transfusion require further 
consideration.
13-15
  
There is similar consistency amongst the transcriptomic data available following tissue damage 
and major surgery.
6, 16, 17
 A striking feature is the elevation in IL-6 levels in patients with features of 
functional immune suppression and the correlation between circulating levels of this cytokine and 
infectious complications. Although many essential pro-inflammatory effects are mediated through IL-6 
pathways this cytokine has also been shown to drive differentiation of T helper cells to a T helper cell 
type 2 (Th2) subtype and to inhibit Th1 maturation through a Suppressor of Cytokine Signalling 1 
(SOCS1) dependent suppression of IFN-γ signalling.18, 19 These latter effects could be broadly construed 
as anti-inflammatory and may induce an immune environment in which host bactericidal abilities are 
impaired, thereby increasing susceptibility to infectious complications. Furthermore, the purported 
mechanism of action suggests that restoring IFN-γ activity may reverse the downstream consequences. 
 6 
 We hypothesised that increased levels of IL-6 following major surgery may promote an 
immunosuppressed phenotype that can be reversed with IFN-γ. In order to explore this hypothesis we 
aimed to describe the patterns of IL-6 production in response to major gastrointestinal surgery and the 
relationship between IL-6 levels and infectious complications. We also aimed to explore the role of IL-6 
dependent pathways in post-operative immune suppression and to determine whether this immune 
suppression might be reversed by IFN-γ.      
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Methods 
 
This study was conducted at The Royal London Hospital, London UK and approved by the North 
Wales Research Ethics Committee (Reference: 10/WNo03/25).  
 
Patient selection 
Consecutive patients aged over 45 years undergoing scheduled surgery involving the 
gastrointestinal tract, requiring a general anaesthetic and at least an overnight hospital stay were 
considered eligible for inclusion to this study. Exclusion criteria were refused consent, emergency surgery 
and surgery which also involved access to the thoracic cavity. Every patient on a weekday elective 
operating list was screened. Eligible patients were then approached for written informed consent. Entry 
into the study did not influence clinical treatment. All patients received perioperative prophylactic 
antibiotic therapy.  
 
Data collection 
Clinical data were collected on each patient until hospital discharge. Pre-operative 
immunosuppression was defined as the administration of chemotherapeutic agents and/or radiotherapy 
within the six months preceding surgery. Patients were examined daily by the clinical team for the 
presence of infection. Definitions of infection were agreed prospectively by the investigators and were 
based on the Center for Disease Control and Prevention (CDC) definitions and graded using the Clavien-
Dindo classification
 
(Supplementary Table 1).
20
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Blood sampling and processing  
Blood samples were taken immediately before induction of anaesthesia (Pre-op), at 24 and 48 
hours following the operation. Plasma was collected from citrated Vacutainer™ tubes (Becton Dickinson, 
UK) centrifuged twice at 3,000 RPM for 10 mins at 20
o
C and stored at -80
o
C until further analysis. Serum 
was collected from BD Vacutainer™ SST™ Serum Separation Tubes (Becton Dickinson, UK), allowed 
to clot for a minimum of 15 minutes and centrifuged at 3,000 RPM for 10 minutes at 20
o
C and stored at -
80
o
C until further analysis. Serum was filtered with an Acrodisc® 32mm 1.2uM syringe filter (VWR, 
UK) prior to use. 
 
Enzyme Linked Immunosorbent Assay (ELISA) 
Plasma samples were assayed in duplicate using commercially available IL-6 ELISAs (Life 
Technologies, Carlsbad, CA) with absorbance measured at 450nm. We have previously attempted to 
quantify IFN-γ levels in plasma from similar patient groups and found levels to be unreliably detectible in 
the majority of patients; consequently we chose not to attempt to measure IFN-γ levels in this population. 
 
In vitro cell culture experiments 
8 mL of peripheral blood was collected in BD Vacutainer™ Sodium Citrate CPT™ tubes (Becton 
Dickinson, UK) from healthy controls (n=6, median age 36, male sex 4 (66.6%)). These were 
immediately centrifuged at 1,800 RCF for 30 minutes at 20
o
C with the brake off. The peripheral blood 
mononuclear cell (PBMC) layer was isolated and washed in Phosphate Buffered saline (Life 
Technologies, Carlsbad, CA) containing 2% human albumin solution. Cells were then counted with a 
haemocytometer.   
Pooled healthy PBMCs were aliquoted (3x10
6 
cells per well) into a 96 well plate and cultured in 
duplicate with Gibco® RPMI 1640 medium (Life Technologies, Carlsbad, CA) containing 30% patient 
serum, which was taken either pre-operatively (pre-op) or at 24hrs post operatively, for 20 hours at 37
o
C 
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with 5% CO2 (CB 150, Binder). The patients from whom perioperative serum was obtained were selected 
in order to have relatively homogenous operation times above a minimum time of 200 minutes 
(Supplementary Table 2 & 3). 
Neutralising experiments: Pooled healthy PBMCs were pre-incubated with an Fc Block™ 
(Becton Dickinson, UK) for 30min then incubated with 30% 24hr serum and media pre-incubated with 
either IL-6 neutralising antibody 15ng/mL (AB-206-NA R&D systems, UK) for a minimum of 1 hour or 
with control non-specific goat IgG at 15ng/mL (AB-108-C, R&D systems, UK). These were cultured as 
described above.  
IL-6 protein was quantified as above in four duplicate patient samples with and without 15ng/ml 
IL-6 neutralising antibody in order to demonstrate the efficacy of the neutralising effect (Supplementary 
figure 1).  
Stimulating experiments: Pooled healthy PBMCs were incubated with 30% serum from either 
baseline or 24hrs with and without IFN-γ (250 International Units, R&D systems, UK). These were 
cultured as described above.  
 
Flow Cytometry 
Following culture, PBMCs were stained in duplicate for 30 minutes at room temperature with a 
combination Quantibrite™ antibody HLA-DR PE/anti Monocyte (CD14) and PerCP-Cy5.5 (Becton 
Dickinson, UK), cells were washed and immediately analysed. 2,000 CD14
+
 cells were collected using an 
LSR II flow cytometer (Becton Dickinson, UK). CD14
+
HLA-DR membrane density (geometric mean 
fluorescent intensity (MFI)) was analysed using FlowJo software 10.0.7 (Tree Star, Ashland, OR) on a 
MAC® workstation by gating on monocytes, via side and forward scatter, then gating on the CD14
+
 
population (Figure 1). 
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Statistical analysis 
Results are expressed as median and interquartile range (IQR). All statistical tests are two-sided 
and a P-value of P<0.05 was considered significant. Differences in categorical variables were calculated 
using a Chi-squared or Fisher’s exact test as appropriate. The Kruskal-Wallis test was used for continuous 
variables and the Wilcoxon signed-rank test for repeated measurements. Multivariable linear regression 
models were used to assess whether IL-6 levels were independently associated with post-operative 
infection. Data analysis was performed using the JMP (version 11) statistical software package (SAS, 
Cary, NC, USA). 
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Results 
 
Patients 
108 patients (mean age 65, range 46–87, 59% male) undergoing elective major abdominal 
surgery were included in this study. 41 (38%) patients developed a post-operative infection. Patient 
characteristics are outlined in Table 1. 
 
Post-operative infections 
Post-operative infectious complications developed a median of 9 (IQR 5–11) days following the 
procedure. The sites of infection and organisms isolated are shown in Table 2. Patients developing 
infections stayed longer in hospital (14 (9–19) vs 7 (5-9) days, P<0.0001). A range of demographic and 
clinical data did not distinguish between those who did and did not develop infection (Table 1).  
 
Perioperative IL-6 levels 
IL-6 levels increased 19-fold from baseline to 24 hours post-operatively (P<0.0001) and were 
unchanged between 24 and 48 hours post-operatively (Figure 2A). Baseline IL-6 levels were higher in 
patients with a diagnosis of cancer, P=0.02; Figure 2B). None of age, sex, smoking history, 
immunosuppression or diabetes was associated with baseline IL-6 levels. At 24 hours higher IL-6 levels 
were observed in patients who would subsequently develop infections (P<0.0001; Figure 3A). This 
association was observed for intra-abdominal infections (P=0.004; Figure 3B) and surgical site infections 
(P=0.001; Figure 3C) but not for pneumonia (P=0.81; Figure 3D). IL-6 levels at 24 hours were directly 
correlated with the length of the procedure (Spearman’s ρ 0.26, P=0.01), were lower in patients who 
underwent endoscopic procedures (24 (12–47) vs 77 (32-136), P=0.0001) and were higher in patients that 
received an epidural (80 (31–172) vs 34 (18–84), P=0.006). No difference was detected in peri-operative 
IL-6 levels between those patients with and without pre-operative immunosuppression (Supplementary 
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Figure 2). A multivariable linear regression model confirmed that the association between IL-6 levels at 
24 hours and post-operative infectious complications remained when corrected for the differences in the 
above variables. This pattern was replicated at 48 hours with IL-6 levels higher in those patients 
subsequently developing infections (P=0.003), higher in patients who had longer procedures (Spearman’s 
ρ 0.26, P=0.02), lower in patients who had endoscopic procedures (P=0.0002) and higher in patients that 
received an epidural (P=0.02). The association between IL-6 levels at 48 hours and infectious 
complications again remained when corrected for these variables. 
 
Effect of post-operative serum on healthy control mHLA-DR expression 
Serum was collected from 8 patients pre-operatively and again at 24 hours. Details of these 
patients are given in Supplementary Table 2. Healthy control mHLA-DR MFI fell when incubated with 
serum collected 24 hours following major surgery when compared with MFI levels following incubation 
with pre-operative serum (Figure 4A, P=0.008, n=8). Pre-incubation with IL-6 neutralising antibody did 
not alter this reduction in MFI (Figure 4B; P=0.95). Serum from a further 8 patients was collected pre-
operatively and at 24 hours (Supplementary Table 3). Again there was a fall in mHLA-DR MFI following 
incubation with serum taken at 24 hours. Co-incubation with IFN-γ resulted in an increase in mHLA-DR 
MFI (P=0.008; figure 4C, n=8). These data were also re-analysed excluding the two patients with pre-
operative immunosuppression. A similar fall in mHLA-DR MFI following incubation with serum taken at 
24 hours was demonstrated which was prevented by co-incubation with IFN-γ (n=6, supplementary figure 
3A & B).   
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Discussion 
In this study we determined plasma levels of IL-6 protein in patients over 45 years of age 
undergoing elective surgery involving the gastrointestinal tract and described an independent association 
between higher post-operative levels of IL-6 and later nosocomial infections. We also demonstrated that 
serum collected in the post-operative period contains soluble mediators, which reduce the antigen 
presenting capabilities of healthy monocytes as measured by HLA-DR expression. Although the causative 
molecules and pathways remain unidentified we report that IL-6 dependent pathways are not essential 
mediators of this immune suppressed phenotype. Treatment with IFN-γ in vitro did, however, reverse the 
induced deficit in the antigen presenting capabilities of monocytes exposed to post-operative serum.  
 The association between IL-6 levels and post-operative infections is not unexpected and has been 
previously described.
21, 22
 Unsurprisingly, we also report that IL-6 levels are higher in those patients 
undergoing lengthier procedures, which are likely to be more complex with a higher probability of post-
operative complications. Importantly, however, we have found that the association between IL-6 levels 
and post-operative infections is independent of the duration of the surgical procedure. It is also well 
recognised that post-operative patients display features of immune suppression.
1, 7
 However, whereas 
previous investigators have reported alterations in the properties of specific cell subtypes or their cell 
surface markers
4, 7
 we demonstrate that immune suppression is mediated, at least in part, by soluble 
compounds that remain 24 hours following surgery, as opposed to the direct effect of either tissue 
damage, anaesthesia or endotoxin release on immune cell subtypes. These data may be of crucial 
importance in developing potential treatments to alleviate post-operative immune suppression.  
 The key link between the tissue damage characteristic of major surgery and the subsequent 
inflammatory response is the release of alarmins.
23
 Alarmins are a group of structurally diverse 
compounds, which include high-mobility-group box (HMGB) proteins and mitochondrial DNA 
(mtDNA), which are released following tissue damage as cells undergo physiological stress or necrosis.
24
 
These are then recognized by a wide variety of pattern recognition receptors (PRRs), which include the 
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membrane bound Toll-like receptors (TLRs) and the cytoplasmic NOD-like receptors (NLRs).
24
 
Activation of PRRs induces an enzymatic cascade, which results in down-stream phosphorylation of 
transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 
which in turn alters cytokine transcription. IL-6 is a cytokine that is consistently upregulated acutely 
following activation of this cascade.
6
 Furthermore, following traumatic injury elevated levels of IL-6 are 
seen concurrently with evidence of immune suppression and reduced antigen presentation capabilities.
25
 
This association, together with the consistent observation that higher IL-6 levels and infectious 
complications are linked following major tissue damage raises the possibility that in this scenario IL-6 
functions not in its traditional pro-inflammatory role but rather to promote an immune suppressed 
phenotype. This hypothesis is supported by evidence from animal models and in vitro data describing the 
anti-inflammatory effects of IL-6 acting through a classical signaling pathway involving the membrane 
bound IL-6 receptor and SOCS1 and STAT3 dependent mechanisms which ultimately inhibit IFN-γ 
production.
18, 19, 26
 Although IL-6 antagonists such as tocilizumab are in clinical use, it is imperative that 
prior to considering their potential use following major surgery evidence is available that the increased 
IL-6 observed in this scenario is of significance as a specific mediator of poor clinical outcomes as 
opposed to being a biomarker of a poor clinical outcome.
27
 In the case of post-operative immune 
suppression our data suggests that although elevated IL-6 levels are associated with clinical correlates of 
immune suppression such as post-operative infectious complications it does not play a key role in 
impairing the antigen presenting capabilities in the post-operative period. Interestingly, it has recently 
been reported that the development of post-operative inflammatory complications and infection in 
particular, is preceded by increased expression of TLR4 and TLR5 on an intermediate (CD14
++
CD16
+
) 
monocyte population.
28
 These same patients displayed higher resting and TLR-stimulated IL-6 levels in 
the early post-operative period in conjunction with enhanced activity in the NF-κB signaling pathway.28  
 We further hypothesised that were IL-6 to play a major role in mediating post-operative immune 
suppression through a pathway that culminates in IFN-γ inhibition19 then supplementation with 
exogenous IFN-γ may reverse these features. Although it appears that the increase in IL-6 levels may not 
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play a causal role in this process our results indicate that IFN-γ independently restores HLA-DR 
expression in affected monocytes. There are conflicting reports in the surgical literature on the effect of 
post-operative IFN-γ administration. In patients with colonic cancer IFN-γ appears to increase HLA-DR 
expression on PBMCs,
29
 whereas in other patients undergoing gastrointestinal surgery IFN-γ administered 
as part of in vitro experiments failed to reconstitute defective pro-inflammatory cytokine production.
29
 
Our data demonstrates that the in vitro administration of IFN-γ can reverse features of defective antigen 
presenting capacity following major surgery in patients both with and without cancer. Our use of a well-
validated, standardized biomarker of immune suppression (mHLA-DR) of particular relevance in the 
prediction of septic complications enhances the potential clinical applicability of these results.
25, 30, 31
  
 There are a number of inherent strengths to our study. We have studied a clinically relevant at-
risk population selected by using age over 45 years old as an inclusion criterion. This ensures that the 
event rate of our primary outcome, infectious complications following elective surgery, is sufficiently 
high at 38% and is in keeping with recent data from similar cohorts.
2
 As all patients were undergoing 
elective surgery this allows each patient in the in vitro study to act as their own control. This is important 
as a significant number of these patients had a diagnosis of cancer or were immunocompromised and the 
use of healthy control serum as a comparator would be inappropriate. Finally, we describe a relatively 
novel method of identifying perioperative immune suppression by culturing healthy monocytes in post-
operative serum in conjunction with the well-validated methodology of defining immune suppression by 
observing a decrease in mHLA-DR expression.
31,
 
32
 
 Limitations of this study include; not assaying circulating IFN-γ protein levels in the post-
operative period and the wide variability in the surgical procedures performed resulting in a 
heterogeneous patient population. We chose not to assay circulating IFN-γ protein levels due to the 
insensitivity of the IFN-γ assay in clinical conditions where in our experience IFN-γ levels are frequently 
undetectable.  
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Conclusions 
 IL-6 levels increase following major surgery and higher levels are associated with an increased 
susceptibility to post-operative infections. Serum obtained from post-operative patients induces an 
immunosuppressive response through IL-6 independent pathways, which is reversible with IFN-γ 
administration. Although, increased IL-6 levels may be useful as a biomarker of impending infectious 
complications our data do not support a causal relationship.     
  
 17 
Acknowledgments 
 
The authors are grateful to the Adult Critical Care Research Team of the Royal London Hospital, Barts 
Health NHS Trust for data collection and blood sampling.  
 18 
References 
 
1. Mokart D, Textoris J, Chow-Chine L, et al. HLA-DR and B7-2 (CD86) monocyte expressions 
after major cancer surgery: profile in sepsis. Minerva Anestesiol. 2011;77:522-7. 
2. Pearse RM, Harrison DA, MacDonald N, et al. Effect of a perioperative, cardiac output-guided 
hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a 
randomized clinical trial and systematic review. JAMA. 2014;311:2181-90. 
3. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory 
responses to injury. Nature. 2010;464:104-7. 
4. Gaudilliere B, Fragiadakis GK, Bruggner RV, et al. Clinical recovery from surgery correlates 
with single-cell immune signatures. Sci Transl Med. 2014;6:255ra131. 
5. Pillay J, Kamp VM, van Hoffen E, et al. A subset of neutrophils in human systemic inflammation 
inhibits T cell responses through Mac-1. J Clin Invest. 2012;122:327-36. 
6. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 
2011;208:2581-90. 
7. Wakefield CH, Carey PD, Foulds S, et al. Changes in major histocompatibility complex class II 
expression in monocytes and T cells of patients developing infection after surgery. Br J Surg. 
1993;80:205-9. 
8. Cheron A, Floccard B, Allaouchiche B, et al. Lack of recovery in monocyte human leukocyte 
antigen-DR expression is independently associated with the development of sepsis after major 
trauma. Crit Care. 2010;14:R208. 
9. Pillay J, Tak T, Kamp VM, et al. Immune suppression by neutrophils and granulocytic myeloid-
derived suppressor cells: similarities and differences. Cell Mol Life Sci. 2013;70:3813-27. 
10. Nakos G, Malamou-Mitsi VD, Lachana A, et al. Immunoparalysis in patients with severe trauma 
and the effect of inhaled interferon-gamma. Crit Care Med. 2002;30:1488-94. 
 19 
11. Dries DJ, Jurkovich GJ, Maier RV, et al. Effect of interferon gamma on infection-related death in 
patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg. 
1994;129:1031-41. 
12. Polk HC, Jr., Cheadle WG, Livingston DH, et al. A randomized prospective clinical trial to 
determine the efficacy of interferon-gamma in severely injured patients. Am J Surg. 
1992;163:191-6. 
13. Matsuoka H, Kurosawa S, Horinouchi T, et al. Inhalation anesthetics induce apoptosis in normal 
peripheral lymphocytes in vitro. Anesthesiology. 2001;95:1467-72. 
14. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. 
Am J Ther. 2004;11:354-65. 
15. Fragkou PC, Torrance HD, Pearse RM, et al. Perioperative blood transfusion is associated with a 
gene transcription profile characteristic of immunosuppression: a prospective cohort study. Crit 
Care. 2014;18:541. 
16. Mokart D, Leone M, Sannini A, et al. Predictive perioperative factors for developing severe 
sepsis after major surgery. Br J Anaesth. 2005;95:776-81. 
17. Baigrie RJ, Lamont PM, Kwiatkowski D, et al. Systemic cytokine response after major surgery. 
Br J Surg. 1992;79:757-60. 
18. Sofi MH, Li W, Kaplan MH, et al. Elevated IL-6 expression in CD4 T cells via PKCtheta and 
NF-kappaB induces Th2 cytokine production. Mol Immunol. 2009;46:1443-50. 
19. Diehl S, Rincon M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 
2002;39:531-6. 
20. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated 
infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 
2008;36:309-32. 
 20 
21. Mokart D, Merlin M, Sannini A, et al. Procalcitonin, interleukin 6 and systemic inflammatory 
response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J 
Anaesth. 2005;94:767-73. 
22. Mokart D, Capo C, Blache JL, et al. Early postoperative compensatory anti-inflammatory 
response syndrome is associated with septic complications after major surgical trauma in patients 
with cancer. Br J Surg. 2002;89:1450-6. 
23. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin 
Immunol. 2005;17:359-65. 
24. Chan JK, Roth J, Oppenheim JJ, et al. Alarmins: awaiting a clinical response. J Clin Invest. 
2012;122:2711-9. 
25. Gouel-Cheron A, Allaouchiche B, Guignant C, et al. Early interleukin-6 and slope of monocyte 
human leukocyte antigen-DR: a powerful association to predict the development of sepsis after 
major trauma. PLoS One. 2012;7:e33095. 
26. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the 
cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878-88. 
27. Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of 
interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and 
other inflammatory conditions. Ann Rheum Dis. 2013;72:482-92. 
28. Lahiri R, Derwa Y, Bashir Z, et al. Systemic Inflammatory Response Syndrome After Major 
Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. Ann Surg. 2015 May 
27; [Epub ahead of print]. Accessed on 07/04/2015. Available at: 
http://journals.lww.com/annalsofsurgery/toc/publishahead. 
29. Wiesenfeld M, O'Connell MJ, Wieand HS, et al. Controlled clinical trial of interferon-gamma as 
postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 1995;13:2324-9. 
 21 
30. Docke WD, Hoflich C, Davis KA, et al. Monitoring temporary immunodepression by flow 
cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. 
Clin Chem. 2005;51:2341-7. 
31. Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to 
reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled 
multicenter trial. Am J Respir Crit Care Med. 2009;180:640-8. 
32. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte 
antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med. 2002;166:1475-82. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
Table 1. Characteristics of patients developing infections and those remaining 
infection free following scheduled abdominal surgery. 
 
 
 
Infection  
n=41 (40%) 
 
Infection free 
n=67 (60%) 
P value 
Age (years) 65 (59 – 75) 64 (57 – 71)   0.36 
Male sex  24 (59) 40 (60) >0.99 
Diabetes  6 (15) 10 (15) >0.99 
Current smokers  8 (20) 12 (18) >0.99 
Smoking history  19 (46) 39 (58)   0.24 
Cancer diagnosis  22 (54) 47 (70)   0.10 
Preoperative immunosuppression  6 (15) 9 (14) >0.99 
Duration of operation (minutes) 245 (178 – 310) 200 (145 – 293)   0.07 
Endoscopic surgery  7 (17) 22 (33)   0.08 
Planned postoperative ICU admission 33 (80) 46 (69)   0.26 
ASA grade 3 or 4  12 (30) 21 (31) >0.99 
By surgical specialty  
General surgery 3 (50) 3 (50)  
Upper gastrointestinal 9 (38) 15 (62)  
Colorectal 17 (36) 30 (64)  
HPB 10 (37) 17 (63)  
HPB + colorectal 1 (33) 2 (67)  
General surgery + colorectal 1 (100) 0 (0)    0.83
1
 
Plasma IL-6 (ELISA) (pg/ml)    
Pre-Op 3.7 (2.8 – 13) 3.0 (2.4 – 4.8)  0.07 
24hrs  101 (49 – 242) 39 (19 – 92)      0.0002 
48hrs  80 (31 – 170) 34 (16 – 79)    0.003 
Data are described as medians with interquartile range or numbers with percentages in parenthesis. ICU, Intensive Care Unit. 
HPB, Hepato-Pancreato-Biliary. 1 represents a Fisher’s exact test incorporating all surgical specialties. 
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Table 2. A description of the infectious complications in the post-operative period. 
Infection site Number of 
episodes 
Organisms 
Median time to 
development of 
infection (days) 
 
Bloodstream Infection 
11 
E. coli (4) 
ESBL  E. coli (1)  
E. coli + E. faecium (1) 
E. faecium (1) 
K. pneumoniae  (1) 
S. aureus (1) 
P. aeruginosa (2) 
 
17 (6 - 28) 
Pneumonia  
9 
Culture negative (5) 
Candida glabrata (1) 
K. pneumoniae  (1) 
Organism of the coliform group (1) 
S. maltophilia  (1) 
 
7 (4 -16) 
Surgical site infection  
24 
Culture negative (11) 
B. fragilis (1) 
E. coli (4), 
ESBL  E. coli (1) 
Mixed anaerobes (1) 
Organism of the coliform group (2) 
Organism of the coliform group + E. 
faecalis (1) 
Organism of the coliform group + 
MRSA(1) 
Organism of the coliform group + S. 
aureus (1) 
P. aeruginosa (1) 
 
10 (4 -14) 
Urinary tract infection 
15 
Candida albicans (1) 
Culture negative (2) 
E. coli (6) 
ESBL  E. coli (1)  
Mixed growth (2) 
Organism of the coliform group (2) 
P. aeruginosa (1) 
 
8 (6 -12) 
Intra-abdominal 
infection 17 
Culture negative (6) 
E. coli (2) 
E. coli + E. faecium (1) 
ESBL  E. coli + VRE(1) 
E. faecalis (1) 
E. faecium + Candida albicans (1) 
Candida albicans (1) 
E. cloacae (1) 
E. cloacae + Organism of the coliform 
group (1) 
E. Aerogenes + P. aeruginosa (1) 
VRE (1) 
 
9 (7 -14) 
Intravascular catheter 
related infection 2 
K. pneumoniae  (1) 
Organism of the coliform group (1) 
15 (3 -27) 
 
   
Data refer to the number of episodes of infection from a particular site. Some patients may have more than one episode of 
infection. The number in parenthesis in the organisms column the number of episodes of infection attributable to that organism. 
ESBL, Extended-spectrum beta-lactamase; MRSA, methicillin-resistant S. aureus; VRE, Vancomycin-resistant Enterococcus. 
Data are described as median and interquartile range. 
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Figure 1: Representative flow cytometry plot of the gating strategy. 
Cells were gated according to their side and forward scatter properties in order to identify the monocyte 
subpopulation. This subpopulation was then gated according to CD14 expression. CD14
+
 cells were then 
analysed for HLA-DR geometric mean intensity (MFI). 
 
 
 
 25 
 
 
 
 
 
 
Figure 2: IL-6 plasma levels, the influence of surgery and pre-operative cancer. 
A: Changes in IL-6 assayed IL-6 plasma concentration following major gastrointestinal surgery. B: Pre-
operative IL-6 protein levels were raised in patients who had a diagnosis of cancer. All data displayed as 
median and interquartile range, pg = picograms, P<0.05 *, P≤0.0001 ****. 
 
 
A B 
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Figure 3: Post-operative IL-6 levels and infectious complications. 
IL-6 concentration assayed at 24 hours between those patients suffering any post-operative infection (A), 
a post-operative abdominal infection (B), a post-operative surgical site infection (C) or a post-operative 
pneumonia (D). Infections were defined according to CDC criteria.
20
 All data displayed as median and 
interquartile range, P≤0.01 **, P≤0.0001 **** 
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Figure 4: Perioperative serum, healthy PBMCs and the effects of IL-6 neutralisation and 
IFN-γ stimulation. A: Post-operative serum decreases the level of mHLA-DR on cultured PBMCs 
obtained from healthy controls. B: The addition of an Fc blocker to the culture medium was necessary to 
eliminate nonspecific antibody actions. In this experiment, in the presence of an Fc blocker, post-
operative serum similarly induced a fall in healthy PBMC mHLA-DR levels. This fall in mHLA-DR 
levels was unchanged when IL-6 was neutralised by the addition of IL-6 antibody at 15ng/ml. C: In 
comparison, when post-operative serum was co-cultured with IFN-γ (250 IU) mHLA-DR levels were 
restored to those levels seen with pre-operative serum. All data (A-C) from two independent 
experiments.  All data displayed as median and interquartile range, HLA-DR quantified as geometric 
median fluorescence intensity (MFI) on CD14
+
 cells, P≤0.01 ** 
 28 
 
 
Pneumonia  
 
Pneumonia requires any 1 of the following:  
1. Rales or dullness to percussion on physical examinations of chest 
AND any of the following: 
A. New onset of purulent sputum or change in character of sputum. 
B. Isolation of organism from blood culture. 
C. Isolation of pathogen from specimen obtained by trans-tracheal aspirate, bronchial brushing, or 
biopsy. 
2. Chest radiography showing new or progressive infiltrate, consolidation, cavitation, or pleural 
effusion. 
AND any of the following: 
A. New onset of purulent sputum or change in character of sputum. 
B. Isolation of organism from blood culture. 
C. Isolation of pathogen from specimen obtained by trans-tracheal aspirate, bronchial brushing, or 
biopsy. 
D. Isolation of virus or detection of viral antigen in respiratory secretions. 
E. Diagnostic single antibody titre (IgM) or fourfold increase in paired serum samples (IgG) for 
pathogen. 
F. Histopathologic evidence of pneumonia. 
 
 
 
 
 
 
 
 
Supplementary Table 1. Criteria used for defining the sites of infection.
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Infection site Definition 
 
 
BSI – Bloodsteam Infection  
(LCBI - Laboratory-Confirmed 
Bloodstream Infection, Secondary 
BSI- Secondary Bloodstream 
Infection) 
 
Laboratory-Confirmed Bloodstream Infection (LCBI) must meet at least 1 of the 
following criteria: 
1. Patient has a recognized pathogen cultured from 1 or more blood cultures. 
AND organism cultured from blood is not related to an infection at another site. 
2. Patient has at least 1 of the following signs or symptoms: fever (>38°C), chills, or hypotension. 
AND signs and symptoms and positive laboratory results are not related to an infection at another 
site. 
AND common skin contaminant is cultured from 2 or more blood cultures drawn on separate 
occasions. 
 
Secondary Bloodstream Infection (BSI) 
In a patient suspected of having an infection, blood and a site-specific specimen are collected for 
culture and both are positive for at least one matching organism. If the site-specific culture is an 
element used to meet the infection site criterion, then the BSI is considered secondary to that site-
specific infection.  
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Supplementary Table 2: Anti-IL-6 Cell culture patient sample demographics 
 
Male  8 (100) 
Age (years) 64 (58 – 74) 
ASA grade 3 or 4 1 (12.5%) 
Operation details  
Elective (%) 8 (100) 
Planned postoperative ICU admission 8 (100) 
Operation length (minutes) 296 (255 – 326) 
Colorectal 2 (25%) 
Upper GI 2 (25%) 
HPB 4 (50%) 
Laparoscopic 2 (25%) 
Cancer 5 (62.5%) 
Preoperatively immunosuppressed  2 (25%) 
Nosocomial Infection 3 (37.5%) 
Surgical Site 2 (25%) 
UTI 1 (12.5%) 
Days post op infection (days) 11, (2-14)  
Plasma IL-6 (ELISA) (pg/ml)  
Pre-Op 2.47 (2.25 – 3.08)  
24hrs 64.91 (41.17 – 93.36)  
48hrs 79.96 (30.33 – 86.11)  
 
Data are described as medians with interquartile range or numbers with percentages in parenthesis. ICU, Intensive 
Care Unit. GI, Gasto-Intestinal. HPB, Hepato-Pancreato-Biliary. 
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Supplementary Table 3: IFN-γ Cell culture patient sample demographics 
 
Male  5 (62.25%) 
Age (years) 60 (52 – 69) 
ASA grade 3 or 4 1 (12.5%)  
Operation details  
Elective 8 (100%) 
Planned postoperative ICU admission 8 (100%) 
Operation length (minutes) 286 (225 – 362) 
Colorectal 3 (37.5%) 
Upper GI 2 (25%) 
HPB 3 (37.5%) 
Laparoscopic 3 (37.5%) 
Cancer 6 (75%) 
Preoperatively immunosuppressed  1 (12.5%) 
Nosocomial Infection 2 (25%) 
Surgical Site 1 (12.5%) 
UTI 2 (25%) 
Pneumonia 1 (12.5%) 
Intra abdominal 1 (12.5%) 
Days post op infection (days) 15.5 (8 – 24)  
Plasma IL-6 (ELISA) (pg/ml)   
Pre-Op 2.74 (2.08 – 3.33)  
24hrs 47.31(27.02 – 176.90)  
48hrs 25.88 (16.68 – 58.63)  
 
Data are described as medians with interquartile range or numbers with percentages in parenthesis. ICU, 
Intensive Care Unit. GI, Gasto-Intestinal. HPB, Hepato-Pancreato-Biliary. 
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Supplementary Figure 1: Efficacy of the IL-6 blocking antibody 
A: Changes in IL-6 protein concentration when post-operative serum was cultured in the presence or 
absence of an IL-6 blocking antibody. All data displayed as median and interquartile range, P<0.05 *. 
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Supplementary Figure 2: Perioperative plasma IL-6 levels in patients with and without pre-
operative immunosuppression  
 
A: Changes in IL-6 protein concentration assayed pre-operatively and at 24 hours post-operatively in patients 
with and without pre-operative immunosuppression. All data displayed as median and interquartile ranges, 
P<0.0001 ****. 
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Supplementary Figure 3: Perioperative serum, healthy PBMCs and the effects of IL-6 
neutralisation and IFN-γ stimulation in patients without pre-operative immunosuppression 
A: The addition of an Fc blocker to the culture medium was necessary to eliminate nonspecific antibody 
actions. In this experiment, in the presence of an Fc blocker, post-operative serum similarly induced a fall 
in healthy PBMC mHLA-DR levels. This fall in mHLA-DR levels was unchanged when IL-6 was 
neutralised by the addition of IL-6 antibody at 15ng/ml. B: In comparison, when post-operative serum 
was co-cultured with IFN-γ (250 IU) mHLA-DR levels were restored to those levels seen with pre-
operative serum. All data (A-B) from two independent experiments.  All data displayed as median and 
interquartile range, HLA-DR quantified as geometric median fluorescence intensity (MFI) on CD14
+
 
cells, P<0.05 *.  
 
 
